ABT · 10-Q · 2026Q3 · Full report

Strategic Business Separation

ABBOTT LABORATORIES · 2026-11-04 · Importance 41 · Surprise 60 · In source text

In October 2026, Abbott announced plans to separate its Nutrition business into an independent, publicly traded company that would include the Nutritional Products segment and brands such as Similac, PediaSure, Pedialyte, Glucerna, and Ensure. Abbott intends to distribute shares of the new company to Abbott shareholders, with the transaction intended to qualify as a tax-free separation for U.S. federal income tax purposes. Abbott expects completion by the end of 2027, subject to customary conditions, regulatory approvals, an effective Form 10 registration statement, and final board approval.

Key facts

• Abbott expects to complete the Nutrition business separation by the end of 2027, subject to customary conditions including regulatory approvals, an effective Form 10 registration statement, and final Abbott board approval. source
• Abbott’s global Nutrition business separation was announced in October 2026 and would create an independent, publicly traded company including the Nutritional Products segment and brands Similac, PediaSure, Pedialyte, Glucerna, and Ensure. source
• Abbott intends to separate its Nutrition business by distributing shares of the independent company to Abbott shareholders; the transaction is intended to qualify as a tax-free separation for U.S. federal income tax purposes. source

Impact estimates